- Home
- NDLS vs TENX Comparison
NDLS vs TENX Comparison
Compare NDLS & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NDLS
- TENX
- Stock Information
- Founded
- NDLS 1995
- TENX 1967
- Country
- NDLS United States
- TENX United States
- Employees
- NDLS N/A
- TENX N/A
- Industry
- NDLS Restaurants
- TENX Biotechnology: Pharmaceutical Preparations
- Sector
- NDLS Consumer Discretionary
- TENX Health Care
- Exchange
- NDLS Nasdaq
- TENX Nasdaq
- Market Cap
- NDLS 29.8M
- TENX 27.3M
- IPO Year
- NDLS 2013
- TENX N/A
- Fundamental
- Price
- NDLS $0.60
- TENX $7.52
- Analyst Decision
- NDLS Buy
- TENX Strong Buy
- Analyst Count
- NDLS 2
- TENX 4
- Target Price
- NDLS $3.00
- TENX $16.67
- AVG Volume (30 Days)
- NDLS 164.5K
- TENX 124.9K
- Earning Date
- NDLS 11-05-2025
- TENX 11-12-2025
- Dividend Yield
- NDLS N/A
- TENX N/A
- EPS Growth
- NDLS N/A
- TENX N/A
- EPS
- NDLS N/A
- TENX N/A
- Revenue
- NDLS $494,752,000.00
- TENX N/A
- Revenue This Year
- NDLS $1.19
- TENX N/A
- Revenue Next Year
- NDLS N/A
- TENX N/A
- P/E Ratio
- NDLS N/A
- TENX N/A
- Revenue Growth
- NDLS N/A
- TENX N/A
- 52 Week Low
- NDLS $0.55
- TENX $3.25
- 52 Week High
- NDLS $1.74
- TENX $7.91
- Technical
- Relative Strength Index (RSI)
- NDLS 39.67
- TENX 76.84
- Support Level
- NDLS $0.61
- TENX $7.45
- Resistance Level
- NDLS $0.69
- TENX $7.91
- Average True Range (ATR)
- NDLS 0.04
- TENX 0.32
- MACD
- NDLS 0.01
- TENX 0.08
- Stochastic Oscillator
- NDLS 23.68
- TENX 79.89
About NDLS Noodles & Company
Noodles & Co is a restaurant concept offering lunch and dinner within the fast-casual segment of the restaurant industry. The company's menu includes a variety of cooked-to-order dishes, including noodles and pasta, soups, salads and appetizers. The company also provides dining, pick-up and delivery services.
About TENX Tenax Therapeutics Inc.
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.